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Decreased tumour [
18F]2-fluoro-2-deoxy-D-glucose (
18FDG) incorporation is related to response however its significance at the cell
level in gastro-oesophageal cancer and how it relates to cell death is unknown. Here human gastric adenocarcinoma (AGS) cells were
treated with lethal dose 10 and 50 (LD10 and LD50), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil
and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer.
18FDG incorporation was determined
after 48 and 72h of treatment with each drug and related to drug-induced changes in glucose transport, hexokinase activity, cell cycle
distribution and annexin V-PE binding (a measure of apoptosis). Treatment of cells for 48 and 72h with LD50 doses of cisplatin
resulted in reductions in
18FDG incorporation of 27 and 25% respectively and of 5-fluorouracil reduced
18FDG incorporation by 34
and 33% respectively: epirubicin treatment reduced incorporation by 30 and 69% respectively. Cells that had been treated for 72h
with each drug were incubated in drug-free media for a further 6 days to determine their ability to recover. Comparison of the ability
to recover from the chemotherapy agent, with
18FDG incorporation before the recovery period allowed an assessment of the
predictive ability of
18FDG incorporation. Cells treated with either 5-fluorouracil or cisplatin demonstrated recovery on removal of
the drug. In contrast, cells treated with epirubicin did not recover corresponding with the greatest 72h treatment decrease in
18FDG
incorporation. In contrast to adherent cells treated with cisplatin or 5-fluorouracil, adherent epirubicin-treated cells also exhibited
very high levels of apoptosis. Glucose transport was decreased after each treatment whilst hexokinase activity was only decreased
after 72h of treatment with each drug. There was no consistent relationship observed between
18FDG incorporation and cell cycle
distribution. Our results show that at the tumour cell level in gastric tumour cells, decreased
18FDG incorporation and glucose
transport, accompanies therapeutic growth inhibition.
18FDG incorporation is particularly diminished in cells exhibiting apoptosis.
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Combination chemotherapy may improve the length and quality of
survival in a proportion of patients with advanced gastro-
oesophageal cancer. With currently available chemotherapy regimens,
only 40–60% of patients will respond to treatment (Gilbert et al,
2002). Present chemotherapy regimens for gastro-oesophageal
cancer include epirubicin, cisplatin and 5-fluorouracil (5-FU). If
patients are to avoid unnecessary treatment with particularly toxic
agents, it is important that non-responders are identified at an
early stage.
A number of studies (Couper et al, 1998; Weber et al, 2001;
Kroep et al, 2003; Ott et al, 2003) have demonstrated that a
reduction in tumour uptake of the glucose analogue, [
18F]2-fluoro-
2-deoxy-D-glucose (
18FDG), is observed during and upon comple-
tion of chemotherapy in gastro-oesophageal cancer. Although
decreased tumour
18FDG uptake has been shown to be associated
with response (and may in fact predict tumour response), its
significance at the gastro-oesophageal tumour cell level is not
known. Response to chemotherapy, as seen on
18FDG-PET with a
corresponding reduction in uptake in solid tumours, may be
related to a decrease in tumour cellularity or a decrease in
18FDG
uptake per cell, or a combination of both. In solid tumours,
tumour cells can recover and it is not known if this decreased
18FDG uptake during response is due to modulation in
18FDG
uptake by cells that will not recover. This reduction in cellular
uptake of
18FDG may occur prior to reduction in tumour volume
and therefore may reflect apoptosis. To further confuse matters, a
flare phenomenon has been recorded in the early period following
exposure to chemotherapy (Basu and Alavi, 2007). In addition
chemotherapy may alter
18FDG cellular uptake by hexokinase (HK)
and/or glucose transport modulation.
The fluorinated glucose analogue,
18FDG, is transported into
tumour cells via a family of glucose transporter proteins, then
phosphorylated by the enzyme HK to
18FDG-6-phosphate after
which it undergoes little further metabolism. Due to low levels of
G-6-Pase in tumour cells this is considered an irreversible reaction
(Weber and Cantero, 1955; Warburg, 1956; Gallagher et al, 1978).
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sHigher levels of HK, namely, HK2 (Torizuka et al, 1995; Mathupala
et al, 1997) and GLUT, especially GLUT1 (Mueckler, 1994; Younes
et al, 1996; Smith, 1999) and low levels of G-6-Pase (Nelson et al,
1996) have been reported in tumour tissue compared with
corresponding normal tissue. Both glut proteins and HK activity
have been implicated as the rate limiting step in cellular
18FDG
uptake (Higashi et al, 1997; Waki et al, 1998; Brown et al, 1999;
Kurokawa et al, 2004; Tohma et al, 2005; Zhao et al, 2005),
although plasma (or media) glucose concentrations may have
more of an impact (Aloj et al, 1999; Zhao et al, 2002; Burrows et al,
2004).
We have determined the effect of three commonly used
chemotherapeutic agents (epirubicin, cisplatin and 5-FU) in the
treatment of upper gastro-intestinal tumours on the cellular
incorporation of
18FDG and on steps associated with its
incorporation, that is, glucose transport and HK activity. As
tumour cells within solid tumours are likely to be exposed to
different drug concentrations, we have treated cells with both
lethal dose 50 (LD50) and drug doses that have a low cell growth
inhibition (LD10, 5–10% cell death). Previous work on AGS
(human gastric adenocarcinoma) cells has shown that they can
recover from treatment with cytotoxic doses of combinational
regimes of 5-FU and cisplatin but not when epirubicin is included
in the combination (Couper and Park, 2003). However, the design
of Coupers’ study meant that this effect could not be specifically
related to epirubicin rather than triple combination chemotherapy.
Our study evaluated the effect of each individual chemotherapeutic
agent. Growth curves for AGS cells were established after exposure
to each epirubicin, cisplatin and 5-FU, with LD10 and LD50
established for each agent at 48h. Growth curves were taken to
216h to determine the extent to which cells were irreversibly
damaged by the chemotherapeutic agents. All subsequent experi-
ments on
18FDG uptake and its relationships to glucose transport,
HK activity, cell viability, cell cycling and apoptosis were under-
taken at 48 and 72h.
The aims of this study were to elucidate the effect, on cellular
(AGS cells)
18FDG incorporation, of exposure to three commonly
used chemotherapeutic agents in the treatment of gastro-
oesophageal cancer and to determine the mechanisms behind
these changes in
18FDG cellular incorporation and their relation-
ship with apoptosis.
MATERIALS AND METHODS
Cell line
A human gastric adenocarcinoma cell line (AGS) (ECACC, Porton
Down, Salisbury, UK) was cultured in HAM F-12 media (Sigma,
Dorset, UK) (supplemented with sodium hydrogen carbonate,
penicillin G, streptomycin sulphate and L-glutamine and 10% fetal
calf serum (Labtech International, East Sussex, UK)) at 371Ci na
humidified incubator with 5% CO2:95% air.
The cells were subcultured in vented 80cm
2 flasks (Nunclon
Delta Surface, Roskilde, Denmark). Cell suspensions were obtained
by trypsinisation (ethylenediaminetetraacetic acid (EDTA)/tryp-
sin) (Sigma) of the adherent cell monolayer, with 5ml of EDTA/
trypsin, when cells reached 70–80% confluence. Cell counts were
performed using a haemocytometer (Bright-Line Haemocytometer,
Sigma).
A seeding density of 7500 cells per 0.35cm
2, based on previous
work (Couper and Park, 2003), was used for all experiments.
Cytotoxicity assays
These were performed to identify the LD10 (5–10% cell death) and
LD50 doses of three chemotherapeutic agents, commonly used in
the treatment of gastro-oesophageal cancers, using the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) as-
say (Mosmann, 1983; Carmichael et al, 1987).
Cells were plated in HAM F-12 media, at optimal seeding
density, and returned to the incubator for 24h to allow cell
adherence to the plate. Media supplemented with varying
concentrations of the chemotherapeutic agents epirubicin (Phar-
macia and Upjohn Ltd., Milton Keynes, UK) (0.0039–0.5mgml
 1),
cisplatin (Faulding Pharmaceuticals, Warwickshire, UK) (0.156–
20mgml
 1) and 5-FU (Faulding Pharmaceuticals) (0.156–
80mgml
 1) was then added and the plate returned to the incubator
for either 48 or 72h. A background of media and a control of
media and cells were also set up.
After 48 or 72h of exposure to the chemotherapy agents, MTT
(Sigma) was added and then incubated for a further 4h at 371C.
Using a scanning multi-well spectrophotometer (Dynatech
MR5000, Dynatech Labarotaries Inc., Chantilly, VA, USA)
measuring spectrophotometric absorbance at 570nm, the plates
were analysed using Biolinx 2.0 software (Biolinx 2.0, Dynatech
Labarotaries Inc.). All experiments were repeated three times with
six replicates per experiment. All subsequent cell work was based
on the LD10 and LD50 concentrations of the chemotherapy agents
at 48h so that time was the only variable.
Quantifying
18FDG uptake
Cells were seeded and incubated for 24h, with control flasks were
seeded at half the optimum seeding density so that cell density
was similar in the control and treated flasks at the time of the
18FDG uptake measurement. Control, LD10 and LD50 flasks were set
up in triplicate and the corresponding concentrations of each
chemotherapeutic agent and returned to the incubator for either 48
or 72h. The incorporation of
18FDG (obtained from the John
Mallard PET Centre, Aberdeen) was determined by incubation of
treated and control cells with
18FDG (1kBqml
 1) for 20min at
371C followed by rapid washing with phosphate buffered saline
(PBS) as described previously (Smith et al, 2006).
18FDG uptake
was expressed relative to protein content (milligram of cellular
protein) and per treated flask.
Protein assay
Protein content was assessed by the bicinchoninic acid protein
assay kit according to the manufacturers’ instructions (Sigma).
Glucose transport
Initially the linear phase of [
3H]O-methylglucose (
3H-OMG)
uptake, a measure of glucose transport (Cloherty et al, 2002),
was determined by incubating cells with
3H-OMG for 1, 2, 3, 5, 15
and 30s.
3H-OMG uptake in control AGS cells was very rapid, with
the linear part of the time activity curve for
3H-OMG uptake at
371C complete within 2s of beginning incubation. Experiments
were, therefore, conducted at 251C with an exposure to
3H-OMG of
1s.
Glucose transport rates were determined at both 48 and 72h
following the addition of required dose of chemotherapeutic agent,
by incubation with media and
3H-OMG (0.5mCiml
 1 (specific
activity 111GBqmmol
 1)), at 251C as described previously (Smith
et al, 2006) except that the incubations were performed for 1s.
3H-OMGuptake was expressed in terms of protein content
(milligram of cellular protein).
Hexokinase activity assay
AGS cells were set up and treated with chemotherapy as per
18FDG
uptake. Following the incubation for 48 or 72h with chemotherapy
the media was removed, and each flask was washed twice with
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sice-cold PBS. Cells were then trypsinised and centrifuged with
the cell pellet washed a further two times with ice-cold PBS.
The resulting cell pellet was then stored at  701C until the HK
activity was assessed based on a modification to the methods by
Miccoli et al (1996) as described previously (Smith et al, 2006).
Enzyme activity was expressed as mUmg
 1 cellular protein
using the extinction coefficient for NADPH of 6.3 
10
3mol
 1cm
 1.
Flow cytometry DNA quantification
AGS cells were set up and incubated in chemotherapy as
previously described for
18FDG uptake. After the required
incubation period the media was discarded and the cells were
harvested and cell cycle distribution was determined as described
previously (Al-Saeedi et al, 2005).
Cell regrowth following exposure to chemotherapy
C e l l sw e r ep l a t e da sf o rM T Ta s s a ya n dt r e a t e df o r7 2hw i t hL D 50 and
LD10 doses of each chemotherapy agent. Following this, the media
was removed and the cells were washed with warm (371C) PBS to
remove any traces of residual chemotherapy. Fresh media (without
chemotherapy) was then added and the plates were returned to the
incubator. After 24, 48, 72, 96, 120 and 144h incubation, MTT assays
were performed to determine the latent cytotoxicity of the
chemotherapeutic agents. Each experiment was repeated in triplicate
with six replicates for each agent and time point.
Annexin V-PE flow cytometry
Annexin V flow cytometry was used to discriminate between intact
cells, early apoptotic and late apoptotic or necrotic cells.
AGS cells were set up as per
18FDG uptake. Control and cells
t r e a t e df o r7 2 hw i t hc h e m o t h e r a p ya g e n t sw e r ed e t a c h e db y
incubating the cells in non-enzymatic cell dissociation solution in
PBS (Sigma) and added to fresh media. The cell concentration was
then adjusted to 3 10
5cellsml
 1,a n d1 m lo ft h i sc e l ls u s p e n s i o n
was then transferred to FACS tubes and centrifuged. The cell pellet
was re-suspended in 1ml of binding buffer (140mM sodium chloride,
25mM calcium chloride, 10mM HEPES (N-(2-hydroxyethyl)piper-
azine-N0-(2-ethanesulphonic acid) hemisodium salt), 500ml distilled
water; Sigma). Following further centrifugation and removal of the
supernatant, 15ml of annexin V staining buffer (10mlV i a - P r o b e( 7 - N
actinomycin D), 5ml annexin V-PE) (BD Biosciences Pharmingen,
Oxford, UK) was added to each cell sample. The samples were stored
in the dark at room temperature for 15min after which 400mlo f
binding buffer was added and annexin V flow cytometry was
performed within 1h, analysing 10000 cell events.
Annexin V flow cytometry was performed on a Becton
Dickinson FACS Calibur (San Jose, CA, USA), and results analysed
using CellQuest software (Becton Dickinson).
Statistics
Results are expressed as means, ±s.e.m..
18FDG,
3H-OMG uptake
and HK activity were expressed as a percentage of the control.
Significance of difference between means was determined by using
the paired t-test (Statistical Package for the Social Sciences V13.1,
SPSS Inc., Chicago, IL, USA), with a P-value of o0.05 indicating
statistical significance.
RESULTS
Cytotoxicity assay
Cytotoxic doses resulting in a 5–10% decrease in cell number
(LD10) and LD50 doses of chemotherapy after 48h exposure were
for cisplatin 0.156 and 5mgml
 1, 5-FU 0.156 and 20mgml
 1 and
epirubicin 0.0039 and 0.125mgml
 1 respectively (Table 1).
Effect of chemotherapy on
18FDG uptake
18FDG uptake per untreated control flask (expressed as cpm per
20min per flask) was 8714±1182 and 14753±986 respectively
after 48 and 72h incubation periods.
18FDG uptake, expressed as
counts per milligram of cells per minute in untreated control
flasks, was 783±94 and 984±35 (cpm per 20min per mg protein)
respectively following 48 and 72h incubation periods.
All three chemotherapeutic agents caused a reduction in
18FDG
uptake per flask of treated cells (Figure 1A and B), with the greatest
reduction occurring following 72h exposure to epirubicin. Upon
48h exposure to LD10 epirubicin, there was a non-significant
reduction in
18FDG uptake per flask (P¼0.104), with a significant
reduction upon exposure to LD50 (P¼0.006) compared with
Table 1 Chemotherapy dose–time relationship and cell death
Cell death, % (±s.e.m.)
Chemotherapy Dose 48h 72h
Epirubicin LD10 4 (4) 5 (2)
LD50 50 (1) 69 (10)
Cisplatin LD10 5 (7) 5 (4)
LD50 56 (7) 77 (12)
5-Fluorouracil LD10 9 (8) 13 (9)
LD50 43 (1) 55 (6)
Results of MTT assay performed at 48 and 72h.
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Figure 1 Cellular [
18F]2-fluoro-2-deoxy-D-glucose (
18FDG) incorpora-
tion, per treated flask, after 48 (A) and 72 (B) h treatment with lethal dose
10 (LD10) (white) and LD50 (grey) doses of epirubicin, 5-FU or cisplatin
expressed as a percentage of incorporation by untreated controls
(E¼epirubicin, C¼cisplatin, F¼5-fluorouracil).
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and 5-FU resulted in a significant reduction in
18FDG uptake per
flask (cisplatin, P¼0.037 and P¼0.001; 5-FU, P¼0.001 and
P¼0.001). Compared with untreated controls there was a
significant reduction in
18FDG uptake per flask following 72h
LD10 and LD50 exposure to epirubicin (P¼0.001 and P¼0.001
respectively), cisplatin (P¼0.001 and P¼0.001 respectively) and
5-FU (P¼0.001 and P¼0.001 respectively).
Exposure to all three chemotherapeutic agents resulted in a
reduction in cellular
18FDG uptake, with the greatest reduction
(63%) occurring on exposure to LD50 epirubicin after 72h
exposure (Figure 2A and B). This dose also produced a high level
of cell death (69%). Compared with untreated controls there was
a significant reduction in
18FDG uptake following 72h LD10
(P¼0.003) and both 48 and 72h exposure to LD50 epirubicin
(P¼0.001 and P¼0.011 respectively), with a non-significant
reduction in
18FDG uptake following 48h incubation at LD10
levels (P¼0.789).
18FDG uptake was significantly decreased in cells
exposed to LD10 (P¼0.01) and LD50 (P¼0.001) doses of 5-FU for
48h exposure. Exposure to 5-FU for 72h resulted in a significant
decrease in
18FDG uptake at LD50 concentration (P¼0.001) whilst
there was little difference between control and LD10 (P¼0.839).
Exposure for 48h to cisplatin, LD10 had little effect on
18FDG
uptake (P¼0.636) in contrast to exposure of LD50, which resulted
in a significant reduction in tracer uptake (P¼0.001). After 72h
exposure to cisplatin there was little further reduction in
18FDG
cellular uptake compared with exposure to 48h LD50.
Effect of chemotherapy on cell cycle
Exposure to LD50 cisplatin and epirubicin resulted in cell cycle
arrest in G2 phase, with LD10 doses resulting in G1 arrest at both 48
and 72h incubation periods. LD10 dose of 5-FU resulted in S phase
arrest, whilst the LD50 caused G1 arrest, irrespective of incubation
periods (Table 2).
Effect of chemotherapy on glucose transport
3H-OMG cellular uptake rate was reduced upon exposure to
epirubicin, cisplatin and 5-FU, with the greatest reduction (35%) in
3H-OMG uptake resulting from 72h exposure to LD50 epirubicin
(Figure 3A and B). Forty-eight hours exposure to LD50 epirubicin,
cisplatin and 5-FU resulted in a significant reduction in cellular
3H-OMG uptake compared to controls (P¼0.037, P¼0.005 and
P¼0.002 respectively) as did 72h exposure (P¼0.002, P¼0.035
and P¼0.001 respectively). LD10 48h exposure resulted in a non-
significant decrease in
3H-OMG uptake for epirubicin, cisplatin
and 5-FU (P¼0.064, P¼0.539 and P¼0.05 respectively). LD10
exposure at 72h caused a significant reduction in uptake for
epirubicin (P¼0.033) but not for cisplatin or 5-FU (P¼0.304 and
P¼0.212 respectively).
Effect of chemotherapy on cellular HK activity
LD10 48h exposure to epirubicin, cisplatin and 5-FU resulted
in a non-significant increase in cellular HK activity (Figure 4A
and B) in comparison to controls (P¼0.575, P¼0.982 and
P¼0.465 respectively). Exposure to 48h LD50, cisplatin and
5-FU also caused a non-significant increase in cellular HK
activity (P¼0.727 and P¼0.282 respectively) whereas with
epirubicin there was a non-significant reduction in HK activity
(P¼0.451).
Exposure to cisplatin and epirubicin for 72h decreased HK
activity, with the greatest reduction caused by exposure to LD50
cisplatin (65%). Hexokinase activity was significantly reduced by
exposure for 72h to cisplatin and 5-FU (cisplatin P¼0.047 and
P¼0.011, 5-FU P¼0.016 and P¼0.018 respectively for LD10 and
LD50). Exposure for 72h to epirubicin caused a significant
reduction in HK activity with the LD50 dose (P¼0.02) but not
the LD10 dose (P¼0.202).
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Figure 2 Cellular [
18F]2-fluoro-2-deoxy-D-glucose (
18FDG) incorpora-
tion, per milligram cellular protein, after 48 (A) and 72 (B) h treatment
with lethal dose 10 (LD10) (white) and LD50 (grey) doses of epirubicin,
5-FU or cisplatin expressed as a percentage of incorporation by untreated
controls (E¼epirubicin, C¼cisplatin, F¼5-fluorouracil).
Table 2 Cell cycle analysis following exposure to chemotherapeutic
agents
Cell cycle, % (±s.e.m.)
Chemotherapy Time (h) Treatment G1 SG 2
Control 48 50 (1) 31 (1) 19 (1)
72 35 (1) 30 (2) 27 (6)
5-Fluorouracil 48 LD10 36 (2) 48 (0) 14 (1)
LD50 77 (1) 9 (0) 16 (1)
72 LD10 14 (1) 64 (3) 19 (1)
LD50 54 (2) 14 (3) 30 (2)
Cisplatin 48 LD10 57 (0) 24 (5) 19 (6)
LD50 30 (1) 22 (0) 47 (1)
72 LD10 48 (1) 27 (2) 24 (1)
LD50 30 (0) 16 (0) 61 (0)
Epirubicin 48 LD10 59 (0) 21 (1) 21 (0)
LD50 31 (1) 13 (3) 59 (2)
72 LD10 46 (1) 25 (2) 28 (1)
LD50 26 (2) 10 (1) 63 (2)
Flow cytometry was performed on a Becton Dickinson FACS Calibur (San Jose, CA,
USA), using blue light (488nm), detecting forward and 901 angle light scatter. Cell
cycle analysis was performed using FlowJo v4.5.2 analysis software (Tree Star Inc., OR,
USA), utilising the Dean–Jett–Fox model, analysing 10000 events.
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sLatent cytotoxicity of chemotherapeutic agents
Following 72h exposure to both LD10 and LD50 of each individual
chemotherapeutic agent, cells were washed and fresh media was
added followed by further incubation for up to 6 days. Cells were
able to recover from exposure to 5-FU and cisplatin when the drug
was removed. However, epirubicin-treated cells did not recover
even after 6 days of incubation in fresh media (Figure 5A–C).
Annexin V-PE flow cytometry revealed that AGS cells exposed to
72h LD50 epirubicin resulted in 69% cell death, 39% of surviving
cells were annexin V-PE positive and 7-AAD negative, indicating
this group of cells were in the early stages of apoptosis (Table 3).
DISCUSSION
Chemotherapy for tumours at or around the gastro-oesophageal
junction is varied, with most regimes including one of epirubicin,
cisplatin or 5-FU (Cunningham et al, 2006). All three chemother-
apeutic agents caused a reduction in
18FDG uptake by AGS cells
with epirubicin having the greatest effect, followed by 5-FU then
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Figure 4 Cellular hexokinase (HK) activity, expressed as milliunits per
milligram of cellular protein as a percentage of control (E¼epirubicin,
C¼cisplatin, F¼5-fluorouracil), after 48 (A) and 72 (B) h exposure to
lethal dose 10 (LD10) (white) and LD50 (grey) doses of epirubicin, cisplatin
and 5-FU (E¼epirubicin, C¼cisplatin, F¼5-fluorouracil).
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Figure 3 Cellular [
3H]O-methylglucose (
3H-OMG) uptake, per milligram
of cellular protein, after 48 (A) and 72 (B) h incubation with lethal dose 10
(LD10) (white) and LD50 (grey) expressed as a percentage of the control
(E¼epirubicin, C¼cisplatin, F¼5-fluorouracil).
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Figure 5 Determination of the growth inhibitory effect of each agent by
performing MTT measurements 6 days after treatment with cisplatin (A),
epirubicin (B) and 5-FU (C) for 72h. Cell survival is expressed as
absorbance as measured on spectrophotometer.
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scisplatin. Previous work on the AGS cell line using the same three
chemotherapeutic agents and exposure times identified similar
LD50 concentrations of each agent, 5-FU 10mgml
 1, cisplatin
10mgml
 1 and epirubicin 0.25mgml
 1 (Couper and Park, 2003). In
common with previous studies, exposure to epirubicin and
cisplatin induced dose-dependent G1 (LD10) and G2 (LD50) cell
cycle arrest (Barry et al, 1990; Sorenson et al, 1990; Shapiro et al,
1998; Zoli et al, 2004). 5-FU exposure resulted in a build up of
cells in S phase (LD10) and G1 (LD50). Epirubicin, an anthracycline
derivative of doxorubicin, exerts its anti-tumour effects via its
action as a DNA intercalating agent and as an inhibitor of
topoisomerase II (Cersosimo and Hong, 1986; Bartkowiak et al,
1992; Zoli et al, 2004). The arrest of AGS cells at higher
concentrations of epirubicin may be related to peak activity of
topoisomerases occurring during the G2 phase (Chow and Ross,
1987). Exposure to cisplatin, an alkylating agent, results in the
binding of cisplatin to DNA, forming cisplatin-DNA adducts which
causes an alteration in the conformation of DNA leading to cell
cycle arrest and apoptosis (Jordan and Carmo-Fonseca, 2000;
Gonzalez et al, 2001; Wang et al, 2004). Cell cycle arrest following
exposure to cisplatin occurs mainly within G2 (Eastman, 1990;
Sorenson et al, 1990), although this may be tumour type dependent
(Sekiguchi et al, 1996; Shapiro et al, 1998). The main mechanism of
action of 5-FU is related to its conversion to 5-fluoro-20-deoxy-
50-monophosphate (via the pyrimidine pathway) leading to the
inhibition of thymidylate synthase and hence DNA synthesis
(Pinedo and Peters, 1988). Studies have revealed an increase
S-phase fraction in tumour cells, caused by 5-FU (Barry et al, 1990;
Yamane et al, 1999; Park et al, 2004), including gastric carcinomas
(Inada et al, 1997).
Dittmann et al (2002), evaluating
18FDG uptake in a squamous
cell carcinoma oesophageal cell line, reported that 24h incubation
periods in concentrations of 5-FU and cisplatin, resulting in 22.8
and 60.6% cell death respectively, had no effect on cellular
18FDG
uptake, following a 24h period of incubation in chemotherapy-free
media prior to uptake experiments. Furthermore, after 24h
exposure to these same concentrations of drugs the S-phase
fraction was elevated considerably, yet had no impact on
18FDG
uptake. Smith et al (2000) investigating tomudex, which is a more
specific thymidylate synthase inhibitor than 5-FU, and oxaliplatin
(a platinum agent similar to cisplatin) on a colonic tumour cell line
found that exposure to tomudex for 24 and 48h resulted in
increasing levels of cellular
3H-DG uptake with increasing
exposure to the agent. This increase in uptake was paralleled with
an increase in the S-phase fraction. The contrasts between these
studies and ours may be in part explained by Yamane et al (1999),
who revealed that although increasingly lengthy exposure to 5-FU
resulted in S-phase accumulation of colorectal cancer cells with
increased apoptosis, the Ki-67 labelling index decreased. There-
fore, this S-phase accumulation is not proliferative but lethal.
Exposure to oxaliplatin (Smith et al, 2000) resulted in decreased
levels of cellular
3H-DG uptake compared to controls with a varied
cell cycle distribution. Although
18FDG uptake in this study was
found to be decreased after treatment with each agent, the effect on
cell cycle was agent-specific suggesting that the changes in
18FDG
uptake are not cell cycle-specific, a finding previously reported by
others (Higashi et al, 1993; Haberkorn et al, 1994).
Recently an analysis (Barros et al, 2005) based on the relation-
ship between HK, glucose transport and intracellular glucose
concentration shows that, at least in neuronal cells, the flux of
glucose through the cell is dependent both on HK and glucose
transport and that appreciable increases in flux require increases
in both of these activities, whereas decreased flux can be brought
about by a reduction in glucose transport or HK activity or both.
Qualitatively, in our study, in each case where a decrease in
18FDG
incorporation is observed there is a corresponding decrease in
glucose transport. By far the greatest decrease in
18FDG
incorporation is observed with the LD50 dose of epirubicin for
72h, which also marginally shows the greatest reduction in glucose
transport. This treatment also causes an appreciable decrease in
HK activity, which may augment the effect of glucose transport on
18FDG incorporation. However, the lack of effect of the LD10 dose
of 5-FU for 72h on
18FDG incorporation or glucose transport,
which caused a significant decrease in HK activity, suggests that
glucose transport is the most important parameter for
18FDG
incorporation in this cell line. Further, regression analysis
performed on pooled 48 and 72h data from each treatment shows
a strong correlation between the changes in FDG incorporation
and glucose transport (t¼0.863, n¼12, Po0.001) but not between
changes in FDG incorporation and HK activity (t¼0.31, n¼12,
P40.1).
One possible reason for the closer association of glucose
transport with
18FDG incorporation compared with HK activity
may be that the glucose transport assay uses intact cells so is a true
measure of the glucose transport of the AGS cell, whereas the HK
assay is performed in cell homogenates. Since HK activity in vivo
is compartmentalised and highly regulated (Smith, 2000), cell
breakage is likely to disrupt these regulatory systems.
We found that
18FDG incorporation was consistently diminished
by treatment with epirubicin, 5-FU or cisplatin. We did not see any
evidence of increased incorporation. Although response to therapy
is generally associated with decreased
18FDG incorporation, a
number of studies (Basu and Alavi, 2007) have reported that
18FDG
incorporation can increase in some responding tumours. In cases
where this ‘metabolic flare’ phenomenon has been observed in
breast tumours treated with anti-oestrogen treatment it has been
attributed to the stimulatory effect of the anti-oestrogen at low
blood concentrations (the situation when the patient begins
therapy) on their cancer cells. A flare phenomenon occasionally
found after radiotherapy generally corresponds with influx of
inflammatory cells into the tumour (Kostakoglu and Goldsmith,
2004). Kubota et al (1992) studying
18FDG uptake in a malignant
murine model discovered that
18FDG accumulated not only within
the tumour cells, but also in the inflammatory components which
appear with growth or tumour necrosis; however, the major source
of
18FDG was still tumour cells. Clearly neither of these situations
is relevant to our treatment/model type.
Another type of hypermetabolism associated with
18FDG has
been reported in both solid tumours (Maruyama et al, 1999) and
cell lines (Fujibayashi et al, 1997). This is likely to reflect
biochemical changes within the cells in response to initial damage.
We determined
18FDG incorporation at times corresponding to
Table 3 Results of annexin V-PE flow cytometry upon 72h exposure to
chemotherapy
Cells, % (±s.e.m.)
Chemotherapy Dose
Annexin V-PE
and 7-AAD
negative
Annexin V-PE
positive and
7-AAD negative
Annexin V-PE
and 7-AAD
positive
Control 93 (1) 4 (1) 2 (0)
Epirubicin LD10 94 (1) 2 (1) 4 (0)
LD50 23 (1) 39 (1) 38 (0)
Cisplatin LD10 95 (0) 3 (0) 2 (0)
LD50 80 (2) 15 (2) 6 (0)
5-Fluorouracil LD10 89 (0) 7 (0) 4 (0)
LD50 93 (2) 3 (1) 4 (2)
Annexin V-PE FACS, 10000 events counted per sample with results displayed as a
percentage of valid counts (annexin V-PE and 7-AAD negative¼healthy cells;
annexin V-PE positive and 7-AAD negative¼early apoptosis; annexin V-PE and
7-AAD positive¼necrosis or late apoptosis).
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complete.
Comparing
18FDG incorporation after 48 and 72h of treatment,
when expressed relative to cellular protein, the decrease in
18FDG
incorporation is seen to plateau for treatment with cisplatin and
5-FU but not with epirubicin in which
18FDG incorporation
continues to decline. This may be explained by the high proportion
(77%) of apoptotic cells in cell populations treated with LD50
epirubicin for 72h compared with cells exposed to cisplatin and
5-FU, suggesting that
18FDG incorporation by apoptotic cells is
decreased compared with viable cells. Following on from this,
determination of the growth inhibitory effect of each agent by
performing MTT measurements 6 days after treatment with each
agent showed that AGS cells can recover from treatment with 5-FU
and cisplatin but not after treatment with epirubicin. In assessing
two chemotherapy regimens for gastro-oesophageal cancer,
Couper and Park (2003) noted that AGS cells exposed to a
combination of LD50 of both cisplatin and 5-FU were able to
recover following clearance of the chemotherapy. The addition of
epirubicin to the combination of cisplatin and 5-FU resulted
in a continual growth inhibitory effect (Couper and Park, 2003).
The nature of Coupers’ study meant that this effect may be due to
the combined effect of three chemotherapeutic agents rather
than specifically related to epirubicin. Engles et al treated MCF-7
breast carcinoma cells for 24h with doxorubicin (an anthracycline
similar to epirubicin) and 5-FU then re-incubated the cells in
chemotherapy-free medium for a further 72h. They found that
cell number in populations treated with doxorubicin continued
to decrease during the 72h in doxorubicin-free medium (Engles
et al, 2006), but addition of 5-FU-free media to MCF-7 cells
treated for 24h with 5-FU was associated with an increase in cell
number indicative of recovery. It appears that the efficacy of
epirubicin is associated with reduced cellular glycolytic rate (Zhou
et al, 2002).
One of the limitations of our study is the extrapolation from in
vitro to in vivo. Our studies are performed on well-perfused cells
with a good nutrient and oxygen supply in an environment with
neutral pH. Within solid tumours in vivo there are regions with
compromised blood flow and consequent nutrient deprivation,
lactic acid production and acidic pH. These are all factors that may
influence
18FDG incorporation. Burgman et al (2001) showed that
induction of hypoxia resulted in increased
18FDG incorporation by
MCF-7 cells whilst HK activity is influenced by environmental pH
(Miccoli et al, 1996). However, the region of tumour growth will
have a good blood supply and is where most of the
18FDG is likely
to reach.
To simulate the uptake of
18FDG within solid tumours,
18FDG
uptake was also expressed as activity per flask. The uptake of
18FDG by detached cells could not be determined as steps to wash
away non-incorporated
18FDG would involve centrifugation, which
would be a problem with detached cells as these are generally late
dying/dead cells with fragile or damaged cell membranes.
However, cells that were undergoing early apoptosis, for example,
cells treated with epirubicin, were still attached and would be
included in the analyses. Furthermore, in vivo, dead cells are
rapidly removed by macrophages. So the contribution of dead cells
in vivo is likely to be small.
In summary, treatment of gastric adenocarcinoma cells with
cisplatin, 5-FU and epirubicin results in decreased
18FDG
incorporation. The greatest reduction in
18FDG uptake per cell is
induced by epirubicin. In contrast to cisplatin and 5-FU treated
cells, epirubicin-treated cells did not recover when the drug was
removed from the medium, corresponding with the annexin V-PE
results, suggesting that the level of change in
18FDG incorporation
is predictive of tumour cell response. Each chemotherapeutic agent
decreased glucose transport suggesting that glucose transport is
the rate-limiting step for
18FDG incorporation by AGS cells.
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